Comparing efficacy of pars planavitrectomy and intravitreal bevacizumab in treatment of diffused non-tractional diabetic macular edema

Trial Profile

Comparing efficacy of pars planavitrectomy and intravitreal bevacizumab in treatment of diffused non-tractional diabetic macular edema

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2012 Recruitment complete, according to the Iranian Registry of Clinical Trials.
    • 11 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top